Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease.
Anca Victorița TrifanAdrian RotaruRemus StafieErmina StratinaSebastian ZenoviaRobert NastasaLaura HuibanTudor CuciureanuCristina Maria MuzicaStefan ChiriacIrina GîrleanuAna-Maria SingeapCatalin Victor SfartiCamelia CojocariuCarol StanciuPublished in: Diagnostics (Basel, Switzerland) (2022)
Non-alcoholic fatty liver disease (NAFLD) has had, over the past few decades, a progressively growing prevalence among the general population all over the world, in parallel with metabolic conditions such as type 2 diabetes mellitus (T2DM), dyslipidemia, and obesity. However, NAFLD is also detected in 10-13% of subjects with a body mass index (BMI) ≤ 25 kg/m² (lean-NAFLD), whose major risk factors remain unknown. In this study, we aimed to characterize the clinical features and associated risk factors of lean-NAFLD in comparison with obese-NAFLD patients. Consecutive patients diagnosed with NAFLD by vibration-controlled transient elastography and controlled attenuation parameter were prospectively enrolled. Biological and clinical data obtained from the participants were stratified according to their BMI in two groups: lean-NAFLD and obese-NAFLD. In total, 331 patients (56.8% males) were included in the final analysis. Most of the subjects were obese-NAFLD ( n = 258, 77.9%) and had a higher prevalence of T2DM, dyslipidemia, and components of the metabolic syndrome, together with abnormal biological parameters. Regarding liver stiffness measurements, the proportion of subjects with at least significant fibrosis (≥F2) was approximately twofold higher among obese-NAFLD (43.81%) in comparison with lean-NAFLD patients (23.29%). Moreover, obese individuals had a higher risk for liver fibrosis (OR = 2.6, 95%, CI 1.5-4.42, p < 0.001) than lean individuals. Although associated metabolic conditions and at least significant liver fibrosis were present in approximately one-quarter of the patients, these were more frequent among obese-NAFLD patients. Therefore, individualized screening strategies for NAFLD should be established according to BMI.
Keyphrases
- metabolic syndrome
- end stage renal disease
- body mass index
- risk factors
- ejection fraction
- newly diagnosed
- chronic kidney disease
- weight loss
- type diabetes
- liver fibrosis
- peritoneal dialysis
- prognostic factors
- cardiovascular disease
- physical activity
- insulin resistance
- bariatric surgery
- weight gain
- subarachnoid hemorrhage
- high frequency